Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) Director David Scott Moore bought 21,700 shares of Corvus Pharmaceuticals stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $11.53 per share, for a total transaction of $250,201.00. Following the transaction, the director directly owned 21,700 shares of the company's stock, valued at approximately $250,201. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Corvus Pharmaceuticals Stock Down 0.3%
NASDAQ:CRVS opened at $11.90 on Tuesday. Corvus Pharmaceuticals, Inc. has a 52 week low of $3.55 and a 52 week high of $26.95. The company has a market capitalization of $1.00 billion, a P/E ratio of -22.88 and a beta of 0.84. The stock's fifty day moving average is $13.95 and its two-hundred day moving average is $13.71.
Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). Sell-side analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Corvus Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Corvus Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company's stock valued at $28,000 after acquiring an additional 748 shares during the period. Quarry LP purchased a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $27,000. Russell Investments Group Ltd. purchased a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $49,000. Teachers Retirement System of The State of Kentucky purchased a new position in Corvus Pharmaceuticals during the 1st quarter valued at about $117,000. Finally, Truvestments Capital LLC boosted its holdings in Corvus Pharmaceuticals by 86.1% during the 4th quarter. Truvestments Capital LLC now owns 10,257 shares of the company's stock valued at $79,000 after acquiring an additional 4,744 shares during the period. 46.64% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Wall Street Zen downgraded Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Oppenheimer reiterated an "outperform" rating and issued a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Weiss Ratings raised Corvus Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, April 29th. Finally, The Goldman Sachs Group initiated coverage on Corvus Pharmaceuticals in a report on Friday, April 17th. They set a "buy" rating and a $40.00 target price for the company. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $33.33.
Check Out Our Latest Research Report on Corvus Pharmaceuticals
About Corvus Pharmaceuticals
(
Get Free Report)
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.
Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
